Summary
AbbVie Inc. (ABBV) announced a significant debt financing transaction via an 8-K filing on February 18, 2025. The company has entered into an underwriting agreement to issue and sell approximately $3.98 billion in aggregate principal amount of senior notes across various maturities in 2028, 2030, 2035, and 2055, with coupon rates ranging from 4.650% to 5.600%. These notes are being issued under AbbVie's existing universal shelf registration statement. The primary purpose of this debt issuance is to refinance upcoming maturities of existing senior notes, specifically addressing the 3.600% senior notes due May 2025 ($3.750 billion), 3.800% senior notes due March 2025 ($2.890 billion), and a portion of Allergan Funding SCS's 3.800% senior notes due March 2025 ($130.225 million). This strategic move aims to manage AbbVie's debt profile and secure long-term funding. The net proceeds, after underwriting discounts, are expected to cover these repayment obligations, with any residual funds designated for general corporate purposes.
Key Highlights
- 1AbbVie is issuing $3.98 billion in new senior notes due 2028, 2030, 2035, and 2055.
- 2The new notes carry coupon rates ranging from 4.650% to 5.600%.
- 3Proceeds will be used to repay or redeem approximately $6.77 billion in existing senior notes maturing in March and May 2025.
- 4This is a proactive debt management strategy to address near-term maturities.
- 5The offering is registered under AbbVie's existing shelf registration statement filed on February 14, 2025.
- 6The closing of the sale is expected on February 26, 2025.
- 7A portion of the funds may also be used for general corporate purposes.